NASDAQ:ZYBT Zhengye Biotechnology (ZYBT) Stock Price, News & Analysis $0.80 +0.02 (+2.56%) Closing price 07/10/2026 03:43 PM EasternExtended Trading$0.76 -0.05 (-5.63%) As of 07/10/2026 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Zhengye Biotechnology Stock (NASDAQ:ZYBT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Zhengye Biotechnology alerts:Sign Up Key Stats Today's Range$0.78▼$0.8250-Day Range$0.65▼$1.0152-Week Range$0.62▼$13.08Volume5,758 shsAverage Volume65,325 shsMarket Capitalization$37.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China. Read More Zhengye Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreZYBT MarketRank™: Zhengye Biotechnology scored higher than 27% of companies evaluated by MarketBeat, and ranked 751st out of 853 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingZhengye Biotechnology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageZhengye Biotechnology has only been the subject of 1 research reports in the past 90 days.Read more about Zhengye Biotechnology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioZhengye Biotechnology has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.09% of the float of Zhengye Biotechnology has been sold short.Short Interest Ratio / Days to CoverZhengye Biotechnology has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zhengye Biotechnology has recently decreased by 59.84%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZhengye Biotechnology does not currently pay a dividend.Dividend GrowthZhengye Biotechnology does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment1.43 News SentimentZhengye Biotechnology has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Zhengye Biotechnology this week, compared to 1 article on an average week. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Zhengye Biotechnology insiders have not sold or bought any company stock.Percentage Held by InstitutionsZhengye Biotechnology has minimal institutional ownership at this time.Read more about Zhengye Biotechnology's insider trading history. Receive ZYBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zhengye Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZYBT Stock News HeadlinesZhengye Biotechnology Faces Nasdaq Minimum Bid Price Deficiency After May 29 NoticeJune 4, 2026 | tipranks.comZhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyJune 4, 2026 | globenewswire.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | Porter & Company (Ad)Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial ResultsApril 28, 2026 | prnewswire.comZhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure Effective April 7, 2026April 6, 2026 | quiverquant.comQZhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share StructureApril 6, 2026 | globenewswire.comZhengye Biotechnology Holding Ltd ZYBTMarch 28, 2026 | morningstar.comMZhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGMMarch 25, 2026 | tipranks.comSee More Headlines ZYBT Stock Analysis - Frequently Asked Questions How have ZYBT shares performed this year? Zhengye Biotechnology's stock was trading at $1.15 on January 1st, 2026. Since then, ZYBT shares have decreased by 30.4% and is now trading at $0.80. How were Zhengye Biotechnology's earnings last quarter? Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) issued its earnings results on Tuesday, April, 28th. The company reported ($0.08) earnings per share for the quarter. The business earned $3.97 million during the quarter. When did Zhengye Biotechnology IPO? Zhengye Biotechnology (ZYBT) raised $6 million in an initial public offering (IPO) on Tuesday, January 7th 2025. The company issued 1,500,000 shares at $4.00 per share. Kingswood Capital Partners acted as the underwriter for the IPO. How do I buy shares of Zhengye Biotechnology? Shares of ZYBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings4/28/2026Today7/12/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZYBT Previous SymbolNASDAQ:ZYBT CIK1975641 Webwww.jlzybio.com Phone86-13844801919FaxN/AEmployees278Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.03 Current Ratio1.14 Quick Ratio0.82 Sales & Book Value Annual Sales$16.64 million Price / Sales2.28 Cash FlowN/A Price / Cash FlowN/A Book Value$0.93 per share Price / Book0.86Miscellaneous Outstanding Shares47,390,000Free FloatN/AMarket Cap$37.91 million OptionableN/A Beta-2.18 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report This page (NASDAQ:ZYBT) was last updated on 7/13/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zhengye Biotechnology Holding Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zhengye Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
